nonyl α-D-glucopyranoside, anhydrous

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: nonyl α-D-glucopyranoside, anhydrous
• 英文别名: 1-nonyl α-D-glucopyranoside；nonyl α-D-glucopyranoside；n-nonyl α-D-glucopyranoside；n-Nonyl a-D-glucopyranoside；(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-nonoxyoxane-3,4,5-triol
• 化学式: C₁₅H₃₀O₆
• 分子量: 306.4
• InChiKey: QFAPUKLCALRPLH-QMIVOQANSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-壬醇 在 三氟化硼乙醚 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 264.0h， 生成 nonyl α-D-glucopyranoside, anhydrous
  参考文献：
  名称：

  Petrovic, Zorica; Konstantinovic, Stanimir; Spasojevic, Aleksandra, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2004, vol. 43, # 1, p. 132 - 134

  摘要：

  DOI：

文献信息

• AMPHIPATHIC COMPOUND HAVING NOVEL PENTA-SACCHARIDE HYDROPHILIC GROUP AND USE THEREOF
  申请人：Industry-University Cooperation Foundation Hanyang University Erica Campus

  公开号：US20190169218A1

  公开（公告）日：2019-06-06

  Disclosed are an amphipathic compound having a penta-saccharide hydrophilic group, a method of preparing the same, and a method of extracting, solubilizing, stabilizing, crystallizing or analyzing membrane proteins and membrane protein complexes using the same. In particular, since the compound has a high-density penta-saccharide hydrophilic group composed of five glucose units, the compound may have an excellent effect on crystallization of membrane proteins. In addition, since the hydrophilic group used in the amphipathic compound has a novel structure, the hydrophilic group may be applied to the development of various amphipathic molecules.

  披露了一种具有戊糖水基团的亲水性化合物，其制备方法以及使用该化合物提取、溶解、稳定、结晶或分析膜蛋白和膜蛋白复合物的方法。特别是，由于该化合物具有由五个葡萄糖单位组成的高密度戊糖水基团，该化合物可能对膜蛋白结晶具有显著效果。另外，由于在两亲性化合物中使用的亲水基团具有新颖的结构，该亲水基团可应用于各种两亲性分子的开发。
• [EN] PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS<br/>[FR] PEPTIDOMIMÉTIQUES POUR LE TRAITEMENT D'INFECTIONS PAR CORONAVIRUS ET PICORNAVIRUS
  申请人：UNIV EMORY

  公开号：WO2020247665A1

  公开（公告）日：2020-12-10

  Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or Hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV- 2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

  用于预防、治疗或治愈人类主体或其他动物宿主中的冠状病毒、小RNA病毒和/或肝炎病毒感染的化合物、组合物和方法。可治疗的特定病毒包括肠病毒。在一个实施例中，这些化合物可用于治疗严重急性呼吸综合征病毒感染，如人类冠状病毒229E、SARS、MERS、SARS-CoV-1（OC43）和SARS-CoV-2。在另一个实施例中，这些方法用于治疗患有两种或更多这些病毒的患者，或一种或多种这些病毒与诺如病毒的组合。
• SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA
  申请人：MacLachlan Ian

  公开号：US20090291131A1

  公开（公告）日：2009-11-26

  The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and/or modifying PLK-1 interfering RNA having immunostimulatory properties. Methods for sensitizing a cell such as a cancer cell to the effects of a chemotherapy drug comprising sequentially delivering PLK-1 interfering RNA followed by the chemotherapy drug are also provided.

  本发明提供了包含干扰RNA（例如siRNA、aiRNA、miRNA）的组合物，这些RNA靶向波洛样激酶1（PLK-1）表达，并提供了使用这些组合物来沉默PLK-1表达的方法。更具体地说，本发明提供了未修饰和化学修饰的干扰RNA分子，这些分子可以沉默PLK-1表达，并提供了它们的使用方法。本发明还提供了含有干扰RNA分子、阳离子脂质和非阳离子脂质的血清稳定核酸脂质颗粒（例如SNALP），这些颗粒还可以进一步包含抑制颗粒聚集的共轭脂质。本发明还提供了通过向哺乳动物主体给予本文描述的干扰RNA分子来沉默PLK-1基因表达的方法。本发明还提供了识别和/或修改具有免疫刺激性能的PLK-1干扰RNA的方法。此外，还提供了一种使细胞（如癌细胞）对化疗药物产生敏感性的方法，包括依次给予PLK-1干扰RNA，然后是化疗药物。
• NOVEL VITAMIN E-BASED AMPHIPATHIC COMPOUND, AND USE THEREOF
  申请人：Industry-University Cooporation Foundation Hanyang University Erica Campus

  公开号：US20200299252A1

  公开（公告）日：2020-09-24

  The present invention relates to a vitamin E-based amphipathic compound, a method for producing same, and a method for extracting, solubilizing, stabilizing, or crystallizing a membrane protein using same. By using a compound according to the present invention, not only is an excellent membrane protein extraction and solubilization effect achieved, but the membrane protein can be stably stored for a long period of time in an aqueous solution, and thus the compound can be utilized in analyzing the function and structure of the membrane protein. Moreover, the vitamin E-based amphipathic compounds exhibited superb properties in the visualization of protein compounds through an electron microscope. Membrane protein structure and function analysis is one of the fields of greatest interest in biology and chemistry today, and since at least half of new drugs currently being developed target membrane proteins, the vitamin E-based amphipathic compounds may be applied to the membrane protein structure research, which is closely related to the development of new drugs.

  本发明涉及一种基于维生素E的两性分子化合物，以及制备该化合物的方法，以及利用该化合物提取、溶解、稳定或结晶膜蛋白的方法。通过使用本发明的化合物，不仅可以实现出色的膜蛋白提取和溶解效果，而且膜蛋白可以在水溶液中稳定存储长时间，因此该化合物可用于分析膜蛋白的功能和结构。此外，基于维生素E的两性分子化合物在通过电子显微镜可视化蛋白化合物方面表现出卓越性能。膜蛋白结构和功能分析是当今生物学和化学领域最感兴趣的领域之一，由于目前至少一半正在开发的新药物针对膜蛋白，因此基于维生素E的两性分子化合物可能被应用于与新药物开发密切相关的膜蛋白结构研究中。
• PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES
  申请人：Mujica-Fernaud Teresa

  公开号：US20100291009A1

  公开（公告）日：2010-11-18

  The invention relates to preparations comprising at least one compound of the formula (I), where the substituents R 1 to R 4 have a meaning indicated in claim 1 , and salts and solvates thereof, and to the use thereof and selected compounds of the formula (I).

  该发明涉及包含至少一种式(I)化合物的制剂，其中取代基R1至R4具有权利要求1中指示的含义，以及其盐和溶剂合物，以及其用途和选择的式(I)化合物。